A Trial of SHR6508 in Secondary Hyperparathyroidism
Status:
Not yet recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the tolerability, pharmacokinetics and
pharmacodynamics of SHR6508 for Chinese patients with secondary hyperparathyroidism of
chronic kidney disease treated by maintenance hemodialysis